SALT LAKE CITY - Recursion, a clinical stage TechBio company listed on NASDAQ:RXRX, introduced a new foundation model named OpenPhenom-S/16, now accessible in the Vertex (NASDAQ:VRTX) AI Model Garden ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Artificial intelligence (AI)-based drug developer Recursion has dosed the first patient in its Phase II ALDER trial (NCT06536465) assessing its first new chemical entity to be developed through its ...
Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...
Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results